BR0012852A - Composto, processo de preparação do mesmo, composição farmacêutica, e utilização de um composto - Google Patents
Composto, processo de preparação do mesmo, composição farmacêutica, e utilização de um compostoInfo
- Publication number
- BR0012852A BR0012852A BR0012852-0A BR0012852A BR0012852A BR 0012852 A BR0012852 A BR 0012852A BR 0012852 A BR0012852 A BR 0012852A BR 0012852 A BR0012852 A BR 0012852A
- Authority
- BR
- Brazil
- Prior art keywords
- alkyl
- compound
- optionally substituted
- present
- aryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Transplantation (AREA)
Abstract
"COMPOSTO, PROCESSO DE PREPARAçãO DO MESMO, COMPOSIçãO FARMACêUTICA, E UTILIZAçãO DE UM COMPOSTO". A invenção refere-se a compostos para o tratamento de condições patológicas ou doenças em que um (ou vários) receptores de somatostatina está (estão) envolvidos, correspondendo a fórmula geral (I) em que R1 representa particularmente um radical arila carbocíclico ou heterocíclico opcionalmente substituído ou um radical heterocíclico não aromático, opcionalmente substituído, R2 representa H, alquila ou arila opcionalmente substituído, R3 representa H ou-(CH~ 2~)~ p~-Z3, Z3 representando particularmente alquila, cicloalquila, bis aril alquila, ou di-aril alquila,-Yl-(CH~ 2~)~ p~-fenila-(Xl)~ n~, arila carbocíclica ou heterocíclica opcionalmente substituída, um radical heterocíclico não aromático opcionalmente substituído, Z1, cada vez que está presente, sendo independentemente selecionado particularmente dentre os radicais H, Cl, F, Br, I, CF~ 3~, NO~ 2~, OH, NH~ 2~, CN, N~ 3~,-OCF~ 3~, alquila, alcoxi,-S-alquila,-(CH~ 2~)p-NH~ 2~,-(CH~ 2~)p-NH-alquila,-(CH~ 2~)~ p~-N-dialquila, Yl representa O, S, NH ou não está presente; R4 representa (CH~ 2~)~ p~-Z4, Z4 representando particularmente amino, alquilamino, N,N-dialquilamino, R5 representa particularmente H ou alquila, X representa 0 ou S, p cada vez que está presente é independentemente 0 ou um inteiro na faixa entre 1 e 6; q cada vez que está presente é independentemente um inteiro entre 1 e 5; n representa 0 ou 1; desde que quando n representa 0, m representa 1, 2 ou 3, e quando n representa 1, m representa 0 ou 1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9909886A FR2796945B1 (fr) | 1999-07-30 | 1999-07-30 | Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments |
PCT/FR2000/002164 WO2001009090A2 (fr) | 1999-07-30 | 2000-07-28 | Derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinoneses, leurs procedes de preparation et leur application a titre de medicaments |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0012852A true BR0012852A (pt) | 2002-04-30 |
Family
ID=9548689
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0012852-0A BR0012852A (pt) | 1999-07-30 | 2000-07-28 | Composto, processo de preparação do mesmo, composição farmacêutica, e utilização de um composto |
Country Status (24)
Country | Link |
---|---|
US (3) | US6759415B1 (pt) |
EP (1) | EP1246807B1 (pt) |
JP (1) | JP2003518011A (pt) |
KR (1) | KR100712587B1 (pt) |
CN (1) | CN1177828C (pt) |
AR (1) | AR024939A1 (pt) |
AT (1) | ATE308525T1 (pt) |
AU (1) | AU779357B2 (pt) |
BR (1) | BR0012852A (pt) |
CA (1) | CA2380070C (pt) |
CZ (1) | CZ2002301A3 (pt) |
DE (1) | DE60023747T2 (pt) |
DK (1) | DK1246807T3 (pt) |
ES (1) | ES2252051T3 (pt) |
FR (1) | FR2796945B1 (pt) |
HK (1) | HK1052510B (pt) |
HU (1) | HUP0202989A3 (pt) |
IL (1) | IL147744A0 (pt) |
MX (1) | MXPA02001016A (pt) |
NO (1) | NO323605B1 (pt) |
NZ (1) | NZ516718A (pt) |
PL (1) | PL364726A1 (pt) |
RU (1) | RU2277093C2 (pt) |
WO (1) | WO2001009090A2 (pt) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0011071D0 (en) * | 2000-05-08 | 2000-06-28 | Novartis Ag | Organic compounds |
JP4711523B2 (ja) * | 2001-02-13 | 2011-06-29 | 日本臓器製薬株式会社 | 低アルブミン血症改善剤 |
HUP0400367A2 (en) * | 2001-06-25 | 2006-03-28 | Conseil De Rech S Et D Applic | Use of somatostatin receptor agonists for preparation of pharmaceutical compositions which inhibit proliferation of pituitary adenomas |
HUP0402489A3 (en) * | 2001-11-28 | 2009-09-28 | Sod Conseils Rech Applic | 5-sulphanyl-4h-1,2,4-triazole derivatives and their use as medicine |
FR2832710B1 (fr) * | 2001-11-28 | 2004-09-03 | Sod Conseils Rech Applic | Derives de 5-sulfanyl-4h-1,2,4-triazoles et leur utilisation en tant que medicaments |
WO2003057214A1 (en) | 2001-12-28 | 2003-07-17 | Somatocor Pharmaceuticals, Inc. | Imidazolidin-2,4-dione derivatives as non-peptide somatostatin receptor ligands |
FR2850652B1 (fr) * | 2003-01-31 | 2008-05-30 | Aventis Pharma Sa | Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
US7354933B2 (en) | 2003-01-31 | 2008-04-08 | Aventis Pharma Sa | Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors |
DE10325813B4 (de) * | 2003-06-06 | 2007-12-20 | Universitätsklinikum Freiburg | Prophylaxe und/oder Therapie bei der portalen Hypertonie |
EP1621535A1 (en) * | 2004-07-27 | 2006-02-01 | Aventis Pharma S.A. | Substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors |
EP1621536A1 (en) * | 2004-07-27 | 2006-02-01 | Aventis Pharma S.A. | Amino cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors |
EP1621539A1 (en) * | 2004-07-27 | 2006-02-01 | Aventis Pharma S.A. | Heterocycle -substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors |
FR2896503B1 (fr) * | 2006-01-23 | 2012-07-13 | Aventis Pharma Sa | Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
FR2896504B1 (fr) * | 2006-01-23 | 2012-07-13 | Aventis Pharma Sa | Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
WO2008017381A1 (de) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung |
NZ590631A (en) | 2006-09-21 | 2011-12-22 | Probiodrug Ag | Novel genes related to glutaminyl cyclase |
US8889709B2 (en) | 2006-09-21 | 2014-11-18 | Probiodrug Ag | Use of isoQC inhibitors in the treatment and prevention of inflammatory diseases or conditions |
US9277737B2 (en) | 2006-09-21 | 2016-03-08 | Probiodrug Ag | Mouse models carrying a knock-out mutation of the QPCTL-gene |
US8710086B2 (en) | 2009-04-09 | 2014-04-29 | Medivation Technologies, Inc. | Substituted di-arylhydantoin and di-arylthiohydantoin compounds and methods of use thereof |
EP2776405A1 (en) * | 2011-11-11 | 2014-09-17 | Pfizer Inc | 2-thiopyrimidinones |
EP3188729A1 (en) * | 2014-09-03 | 2017-07-12 | Genzyme Corporation | Cyclic urea compounds as tropomyosin-related kinase (trk) inhibitors |
WO2022206742A1 (zh) * | 2021-03-30 | 2022-10-06 | 苏州开拓药业股份有限公司 | 一种一步法合成乙内酰硫脲衍生物的方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0912551A1 (en) * | 1996-05-14 | 1999-05-06 | Novo Nordisk A/S | Somatostatin agonists and antagonists |
WO1998013045A1 (fr) * | 1996-09-24 | 1998-04-02 | Taiho Pharmaceutical Co., Ltd. | Inhibiteurs de metastases cancereuses contenant des derives d'uracile |
US6025372A (en) * | 1997-04-04 | 2000-02-15 | Merck & Co., Inc. | Somatostatin agonists |
PT1019050E (pt) | 1997-06-24 | 2002-09-30 | Novo Nordisk As | Utilizacao de agonisticos e de antagonisticos de somatostatina para o tratamento de doencas associadas ao olho |
CN1319094A (zh) * | 1998-06-12 | 2001-10-24 | 研究及应用科学协会股份有限公司 | 咪唑基衍生物 |
NZ508765A (en) * | 1998-06-12 | 2003-10-31 | Sod Conseils Rech Applic | Beta-carboline derivatives and pharmaceuticals thereof that selectively bind somatostatin receptor subtypes |
RU2242481C2 (ru) | 1998-06-16 | 2004-12-20 | Сосьете Де Консей Де Решерш Э Д'Аппликасьон Сьентифик Сас | Аналоги циклического соматостатина |
-
1999
- 1999-07-30 FR FR9909886A patent/FR2796945B1/fr not_active Expired - Fee Related
-
2000
- 2000-07-25 AR ARP000103851A patent/AR024939A1/es active IP Right Grant
- 2000-07-28 DK DK00958634T patent/DK1246807T3/da active
- 2000-07-28 AT AT00958634T patent/ATE308525T1/de not_active IP Right Cessation
- 2000-07-28 IL IL14774400A patent/IL147744A0/xx not_active IP Right Cessation
- 2000-07-28 PL PL00364726A patent/PL364726A1/xx not_active Application Discontinuation
- 2000-07-28 NZ NZ516718A patent/NZ516718A/xx not_active IP Right Cessation
- 2000-07-28 ES ES00958634T patent/ES2252051T3/es not_active Expired - Lifetime
- 2000-07-28 CZ CZ2002301A patent/CZ2002301A3/cs unknown
- 2000-07-28 JP JP2001514294A patent/JP2003518011A/ja active Pending
- 2000-07-28 US US10/048,144 patent/US6759415B1/en not_active Expired - Fee Related
- 2000-07-28 BR BR0012852-0A patent/BR0012852A/pt not_active Application Discontinuation
- 2000-07-28 RU RU2002105024/04A patent/RU2277093C2/ru not_active IP Right Cessation
- 2000-07-28 MX MXPA02001016A patent/MXPA02001016A/es active IP Right Grant
- 2000-07-28 EP EP00958634A patent/EP1246807B1/fr not_active Expired - Lifetime
- 2000-07-28 CN CNB008110654A patent/CN1177828C/zh not_active Expired - Fee Related
- 2000-07-28 KR KR1020027001224A patent/KR100712587B1/ko not_active IP Right Cessation
- 2000-07-28 WO PCT/FR2000/002164 patent/WO2001009090A2/fr active IP Right Grant
- 2000-07-28 HU HU0202989A patent/HUP0202989A3/hu unknown
- 2000-07-28 DE DE60023747T patent/DE60023747T2/de not_active Expired - Lifetime
- 2000-07-28 CA CA2380070A patent/CA2380070C/fr not_active Expired - Fee Related
- 2000-07-28 AU AU70091/00A patent/AU779357B2/en not_active Ceased
-
2002
- 2002-01-29 NO NO20020463A patent/NO323605B1/no not_active IP Right Cessation
-
2003
- 2003-07-08 HK HK03104848.3A patent/HK1052510B/zh not_active IP Right Cessation
-
2004
- 2004-03-30 US US10/813,139 patent/US7199145B2/en not_active Expired - Fee Related
-
2006
- 2006-06-01 US US11/444,769 patent/US7332517B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0012852A (pt) | Composto, processo de preparação do mesmo, composição farmacêutica, e utilização de um composto | |
HRP20080113T3 (en) | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto | |
MXPA04001016A (es) | Derivados de sulfonamida como inhibidores de la gamma secretasa. | |
HUP0301514A2 (hu) | Benzimidazol származékok, elżállításuk és ezeket tartalmazó gyógyszerkészítmények | |
BRPI0315188B8 (pt) | composto e composição farmacêutica | |
HUP0100142A2 (hu) | Szubsztituált ciklopentán- és ciklopenténszármazékok és alkalmazásuk neuraminidáz-inhibitorokként | |
DE69310501T2 (de) | Chinolylbenzofuran derivate als leukotrien-antagonisten | |
TW200420542A (en) | A compound having TGF β inhibition activity and a medicinal composition containing the same | |
MXPA04001240A (es) | Analogos antitumorales. | |
HUP0102404A2 (hu) | N-acilezett gyűrűs aminszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények | |
HUP0401067A2 (hu) | Defenilazetidinon-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
NZ514095A (en) | Amide compounds and medicinal use thereof | |
BR0012647A (pt) | Composto, processo de preparação do mesmo, produto, composição farmacêutica, e utilização do produto | |
HUP0402235A2 (hu) | 4,4-Difluor-1,2,3,4-tetrahidro-5H-1-benzazepin-származékok és ezek sói és ezeket tartalmazó gyógyszerkészítmények | |
BRPI0407695A (pt) | compostos, processo para a preparação de um composto, composições farmacêuticas que compreendem o composto, utilização dos compostos e processo de tratamento para diabetes do tipo 2 | |
PL376324A1 (en) | Piperazinyl and diazapanyl benzamides and benzthioamides | |
HUP0201475A2 (hu) | Heteroarilamidin-, metilamidin- és guanidinszármazékok, előállításuk és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények | |
TW200745048A (en) | Novel benzimidazole and benzothiazole derivatives, preparation process therefor, application thereof as medicaments, pharmaceutical compositions and novel use especially as CMET inhibitors | |
DE69933885D1 (de) | Triphenylbutenderivate zur behandlung von neurologischen störungen | |
HUP0402341A2 (hu) | Szubsztituált tiazol-2-ilaminokat tartalmazó készítmények rák kezelésére | |
CO5160261A1 (es) | Derivados de bifenilo sustituidos que son antagonistas nk-1, su procedimiento de sintesis y composiciones farmaceuticas que los contienen | |
HUP0303694A2 (hu) | Aza-aminosav-származékok és ezeket tartalmazó gyógyszerkészítmények | |
WO2002074777A3 (en) | Pyranocoumarin compounds as a novel pharmacophore with anti-tb activity | |
ATE149494T1 (de) | Benzopyranderivate und verfahren zu deren herstellung | |
HUP0000966A2 (hu) | Izoflavonszármazékok és ilyen vegyületeket hatóanyagként tartalmazó gyógyszerkészítmények |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |